Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Sunday, April 26

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO) (870)

Stewart Tepper, Richard Lipton, Stephen Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David Dodick, Feng Zhang, Sunfa Cheng, Daniel Mikol
First published April 14, 2020,
Stewart Tepper
1Geisel School of Medicine At Dartmouth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Lipton
2Albert Einstein College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Silberstein
3Jefferson Headache Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Kudrow
4David Kudrow MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Messoud Ashina
5Danish Headache Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Reuter
6Charité – Universitätsmedizin Berlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Dodick
7Mayo Clinic Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feng Zhang
8Amgen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunfa Cheng
8Amgen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Mikol
8Amgen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO) (870)
Stewart Tepper, Richard Lipton, Stephen Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David Dodick, Feng Zhang, Sunfa Cheng, Daniel Mikol
Neurology Apr 2020, 94 (15 Supplement) 870;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate the long-term efficacy of erenumab in CM patients with/without AMO.

Background: Patients with CM and AMO are often difficult to treat and represent an unmet need. Erenumab, an anti-CGRP receptor monoclonal antibody for migraine prevention, has efficacy in this patient population.

Design/Methods: This is a subgroup analysis of the 52-week, open-label extension (OLE) of a double-blind study evaluating erenumab in patients with CM. In the parent study, patients received placebo, 70mg erenumab, or 140mg erenumab monthly for 3 months. Patients then received 70mg or 140mg erenumab monthly in the OLE. Change from parent study baseline in monthly migraine days (MMD) and acute migraine-specific medication use days (MSMD) during the OLE were analyzed for 52-week completers by last dose received for patients with/without AMO.

Results: 252/609 (41%) patients in the OLE had AMO at parent study baseline; 77% of AMO and non-AMO patients completed 52 weeks of treatment. For the 70mg and 140mg groups, respectively, mean (95% CI) change from baseline in MMD was −8.9 (−10.3, −7.5) and − 10.0 (−11.9, −8.0) in AMO patients and −8.2 (−9.3, −7.1) and −10.8 (−12.0, −9.6) in non-AMO patients; ≥50% reductions in MMD (95% CI) occurred in 53% (43, 63) and 61% (49, 72) of AMO patients and 53% (44, 62) and 71% (62, 79) of non-AMO patients; and mean (95% CI) change from baseline in MSMD was −7.0 (−8.1, −5.8) and −6.4 (−8.0, −4.9) in AMO patients and −3.5 (−4.3, −2.7) and −4.0 (−5.0, −3.1) in non-AMO patients. Among patients overusing simple analgesics, triptans, or combination therapy at baseline, 81% (43/53), 72% (140/195), and 70% (162/232), respectively, transitioned to non-overuse at week 52.

Conclusions: CM patients with/without AMO treated with erenumab had sustained reductions in MMD with remission of overuse in ≥70% of cases.

Disclosure: Dr. Tepper has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consultant and/or Advisory Boards: Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, ATI, Axsome Therapeutics, Cefaly, Charleston Labs, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, GLG, Guidepoint Global, Magellan Rx Management, Neurolief, N. Dr. Tepper has received personal compensation in an editorial capacity for Headache Currents, Headache, Wiley Blackwell, American Headache Society. Dr. Tepper has received research support from Alder, Allergan, Amgen, ATI, Dr. Reddy’s, ElectroCore, eNeura, Scion Neurostim, Teva, Zosano.Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation the National Headache Foundation and Amgen.Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abide Therapeutics; Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; Cefaly; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Health Holdings, LLC.; eNeura Inc.; electroCore Medical, LLC; Impel NeuroPharma, Inc.; Lilly USA, LLC; Medscape, LLC; Novartis, Inc.; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.Dr. Kudrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly, Amgen, Novartis, Alder, Biohaven, and Teva. Dr. Kudrow has received research support from Amgen, Lilly, Teva, Alder, Allergan, Biohaven, Axome, and Electrocore.Dr. Ashina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder BioPharmaceuticals, Allergan, Amgen, Alder, Eli Lilly, Novartis, and Teva. Dr. Reuter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting%20fee%2C%20speaking%2Fteaching%20fee%2C%20from%20Allergan%2C%20Amgen%2C%20Autonomic%20Technologies%2C%20CoLucid%2C%20ElectroCore%2C%20EliLilly%2C%20Medscape%2C%20Novartis%2C%20StreamMedUp%2C%20%20TEVA%20Pharmaceuticals. Dr. Reuter has received research support from research%20grants%20from%20Allergan%2C%20Amgen%2C%20Autonomic%20Technologies%2C%20CoLucid%2C%20ElectroCore%2C%20EliLilly%2C%20Medscape%2C%20Novartis%2C%20StreamMedUp%2C%20%20TEVA%20Pharmaceuticals.David W. Dodick, MD, reports the following conflicts: Personal fees: AEON, Alder BioPharmaceuticals, Allergan, Amgen, Amzak Health, Association of Translational Medicine, Autonomic Technologies, Axsome, Biohaven, Charleston Laboratories, Clexio, Daniel Edelman Inc., Dr Reddy’s Laboratories/Promius, electroCore LLC, Eli Lilly, eNeura, Equinox, Foresite Capital, Impel, Ipsen, Neurolief, Nocira, Novartis, Oppenheimer, Pieris, PSL Group Services, Revance, Salvia, Satsuma, Sun Pharma (India), Supernus, Teva, Theranica, University Health Network, Upjohn (Division of Pfizer), Vedanta, WL Gore, XoC, Zosano, and ZP Opco; Speaking fees: Amgen, Eli Lilly, Lundbeck, and Novartis Canada; CME fees or royalty payments: Academy for Continued Healthcare Learning, Cambridge University Press, Catamount, Chameleon, Global Access Meetings, Global Life Sciences, Global Scientific Communications, Haymarket, HealthLogix, Medicom Worldwide, MedLogix Communications, Mednet, Miller Medical, Oxford University Press, PeerView, Universal Meeting Management, UpToDate (Elsevier), WebMD Health/Medscape, and Wolters Kluwer Health; Consulting without fee: Aural Analytics, Epien, Healint, Second Opinion/Mobile Health; Professional society fees or reimbursement for travel: American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, Canadian Headache Society, and International Headache Society. Dr. Dodick has received compensation for serving on the Board of Directors of Epien, King-Devick Technologies, Matterhorn, Ontologics, and Precon Health. Dr. Dodick has received research support from American Migraine Foundation, Henry Jackson Foundation, PCORI, and US Department of Defense.Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Amgen Inc.. Dr. Cheng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen. Dr. Mikol has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Amgen Inc.. Dr. Mikol has received compensation for serving on the Board of Directors of Amgen Inc.. Dr. Mikol holds stock and/or stock options in Amgen Inc..

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise